A comprehensive literature search was conducted on PubMed, MEDLINE, Scopus, and ClinicalTrials.gov for randomized controlled trials (RCTs) that evaluated the clinical effectiveness of SGLT2 inhibitors or MRAs when used to treat heart failure, published up to June 6, 2025. This evidence concerns the gene SLC5A2 and heart failure.